How can we prevent multisystem complications of cystic fibrosis?

被引:13
作者
Elborn, J. Stuart
机构
[1] QUB, Resp Med Grp, Belfast, Antrim, North Ireland
[2] BCH, No Ireland Adult Cyst Fibrosis Ctr, Belfast, Antrim, North Ireland
关键词
cystic fibrosis; inflammation; osteoporosis; diabetes; liver disease;
D O I
10.1055/s-2007-981651
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Cystic fibrosis (CF) is a multisystem disease. Some of this is accounted for by CF transmembrane regulator (CFTR) dysfunction in individual organs but in some cases this is compounded by the effects of systemic inflammation. The inflammation is in response to the chronic infection in the airways and is particularly important as a contributor to CF-related bone disease, CF-related diabetes mellitus, CF-related arthropathy, and vasculitis. Preventing these multisystem complications is difficult. Aggressive specific therapies to treat complications is critically important to maintain nutrition, stop the damaging effects of diabetes, and improve bone mineral density. Aggressive treatment of lung disease to reduce systemic inflammation is likely to be of benefit in preventing the development of CF-related bone disease and may be beneficial in at least delaying the onset of CF-related diabetes. Aggressive treatment of pulmonary infection and inflammation in conjunction with holistic management plans to treat specific organ diseases is an important strategy in improving morbidity and reducing mortality in people with CF.
引用
收藏
页码:303 / 311
页数:9
相关论文
共 84 条
[11]   Resting energy expenditure and oxygen cost of breathing in patients with cystic fibrosis [J].
Bell, SC ;
Saunders, MJ ;
Elborn, JS ;
Shale, DJ .
THORAX, 1996, 51 (02) :126-131
[12]  
Bell SC, 2000, EUR J CLIN INVEST, V30, P553
[13]  
Bell Scott C, 2002, J Cyst Fibros, V1, P47, DOI 10.1016/S1569-1993(02)00031-0
[14]   URSODEOXYCHOLIC ACID FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS - A PLACEBO-CONTROLLED TRIAL [J].
BEUERS, U ;
SPENGLER, U ;
KRUIS, W ;
AYDEMIR, U ;
WIEBECKE, B ;
HELDWEIN, W ;
WEINZIERL, M ;
PAPE, GR ;
SAUERBRUCH, T ;
PAUMGARTNER, G .
HEPATOLOGY, 1992, 16 (03) :707-714
[15]   The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis [J].
Bishop, MD ;
Freedman, SD ;
Zielenski, J ;
Ahmed, N ;
Dupuis, A ;
Martin, S ;
Ellis, L ;
Shea, J ;
Hopper, I ;
Corey, M ;
Kortan, P ;
Haber, G ;
Ross, C ;
Tzountzouris, J ;
Steele, L ;
Ray, PN ;
Tsui, LC ;
Durie, PR .
HUMAN GENETICS, 2005, 118 (3-4) :372-381
[16]   Insulin-like growth factor-1, leptin, body composition, and clinical status interactions in children with cystic fibrosis [J].
Boguszewski, Margaret C. S. ;
Kamoi, Tsukiyo Obu ;
Radominski, Rosana Bento ;
Boguszewski, Cesar Luiz ;
Rosberg, Sten ;
Rosario Filho, Nelson Augusto ;
Neto, Romolo Sandrini ;
Albertsson-Wikland, Kerstin .
HORMONE RESEARCH, 2007, 67 (05) :250-256
[17]   Gain in bone mineral mass in prepubertal girls 3.5 years after discontinuation of calcium supplementation: a follow-up study [J].
Bonjour, JP ;
Chevalley, T ;
Ammann, P ;
Slosman, D ;
Rizzoli, R .
LANCET, 2001, 358 (9289) :1208-1212
[18]   Failure of high-dose ergocalciferol to correct vitamin D deficiency in adults with cystic fibrosis [J].
Boyle, MP ;
Noschese, ML ;
Watts, SL ;
Davis, ME ;
Stenner, SE ;
Lechtzin, N .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (02) :212-217
[19]  
BOYLE MP, 2005, PEDIAT PULMONOL, V28, P353
[20]   Pulmonary function, inflammation, exercise capacity and quality of life in cystic fibrosis [J].
Bradley, J ;
McAlister, O ;
Elborn, S .
EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (04) :712-715